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1. Introduction 
Neurocysticercosis (NCC) is still an endemic disease in most of the countries of Asia, Africa 
and Latin America, despite the important progress made in the development of effective tools 
for its prevention, diagnosis and treatment. Although the infection disappeared in many 
European countries during the nineteenth century, in some Eastern European countries 
control was not achieved until the beginning of the twentieth century, mainly due to the 
improvement of their political, social and economic status. Alarming recent reports show the 
persistence of the endemia in Africa [1-3] (Table 1), as well as in the Americas [25] (Table 2) 
and in Asia (Table 3). None of the endemic countries has been able to eradicate Taenia 
solium´s Taeniosis/Cysticercosis (T/C). Similarly, the frequency of human cases of NCC is 
increasing in some industrialized countries, such as the United States, Canada and Spain, due 
mostly to migrant workers, although some autochthonous cases have also occurred [92-97]. 
In this paper, we will try to understand the reasons behind such failures and propose 
strategies that can improve the control of the T/C. 
2. Actual tools for diagnosis and treatment 
It is clear that there are efficient tools for diagnosis and treatment, although investigations 
must surely go on and progress will be made.  
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Country Reference Type of study 
Subject 
included 
Diagnosis 
based on 
Seroprevalence 
Cysticercosis 
Prevalence 
NCC 
Burkina Faso 
[4] 
Population- 
based 
763 Ag-ELISA 10,3%; 1.4%; 0%  
[5] Population-based 734 Ag-ELISA 4.5%  
Burundi 
[6] Case-control 
324 PWE 
648 controls
Ab-ELISA 
59.6 % PWE     
31,5% controls 
 
[7] PWE 250 Ab-ELISA 61%  
[8] Case-control 
303 PWE 
606 Controls
Ab/Ag -
ELISA 
Ab 58,7% ; Ag 
38,3 PWE 
Ab 31, 4%  Ag 
20 % controls 
 
[9, 10] Population-based 168 Ab-ELISA 1,2%  
[11] Population-based 500 EITB 25,8%  
Cameroon 
[12] 
Population- 
based 
137 Butchers
198 Controls
Ag-ELISA 
Butchers 3,6% 
Controls: 4,5% 
 
[13] 
Population- 
based 
504 PWE 
Ab/Ag 
ELISA 
1,2% Ag 44,6% 
Ab 
 
[14] 
Population- 
based 
4993 
Ag-ELISA 
CT scan 
0,4%  1,0 % 
3,0% 
59.1% of 
sero+ 
[15] 
Population- 
based 
93 PWE 
81Controls 
Ab-ELISA 
18,3% PWE 
14,8% Controls 
 
Democratic 
Republic of 
Congo 
[16] Population-based 943 Ag-ELISA 21.6%  
Madagascar 
[17] Population-based 4375 
Ab-ELISA 
EITB 
7-21%  
[18] US Peace Corps 73 EITB 8,2%  
Mozambique [19] Urban children 269 Abs 20,8%  
Senegal [20] Population-based 403 
Ag-ELISA 
EITB 
CT scan 
11,9% 
23,3% of 
sero+ 
South Africa [21] PWE (Hospital) 92 CT scan  37% 
Tanzania [22, 23] Hospital-based 212 PWE CT scan  16.5% 
Zambia [24] Population-based 708 Ag-ELISA 5,8%  
Table 1. Prevalence (sero prevalence) of human neurocysticercosis in Africa.  
Only 2002-2012 articles were considered. 
Improvement of neuroimaging techniques permits a sensitive and accurate diagnosis of 
NCC in the great majority of cases, the problem being its limited accessibility to the 
principal rural population. Immunodiagnosis based on serum antibody detection is an 
efficient marker of contact with the parasite, permitting the identification of endemic areas 
in which control and preventive measures must be intensified. Detection of parasite 
antigens in serum and cerebrospinal fluid permits a confident diagnosis of severe 
neurocysticercosis forms, allowing opportune and adequate treatment and reducing the 
morbidity [98]. Regarding NCC treatment, two cestocidal drugs (Praziquantel and 
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Albendazole) have been used for at least 30 years. Although different studies evaluating 
their efficacy have shown that these drugs are not efficient in all patients, they also revealed 
that they eliminate the parasites and diminish the symptomatology significantly more than 
placebo [99-101]. As a consequence, investigation in this area must continue.  
 
Country Reference Type of study 
Subject 
included 
Diagnosis 
based on 
Seroprevalence 
Cysticercosis 
(%) 
Prevalence 
NCC 
Bolivia [26] Population-based
10124 (124 
PWE) 
EITB 
CT-scan 
 27.4% PWE 
Brazil 
[27] Blood donors 1133 Ab-ELISA 5.6  
[28] Population-based 694 EITB 1.6  
[29] Hospital-based 36379 CT-scan  0.20% 
[30] Population-based 110 PWE 
EITB, 
Ag-ELISA 
8.2 (EITB) 
3.6 (ELISA) 
 
[31] Hospital-based 5 105 259 Admission  0.01% 
[32] Population-based 354 
Ab-ELISA, 
EITB 
11.3  
[33] Population-based 84 Ab-ELISA 5.9  
[34] Population-based
Deaths Sao 
Paulo state 
Death 
certificate 
 
0.55/1000,00
0** 
[35] Hospital-based 1501 Autopsies  4.80** 
[36] Hospital-based 1009 CT-scan  9.02 
[37] Hospital- based 6500 Autopsies  0.80 
Colombia 
[38] Hospital based 
Psychiatric 
patients with 
neurological 
signs (98) 
Primary 
psychiatric 
patients (153)
Controls (246)
EITB 
Group 1: 5.1 
Group 2: 2.6 
Group 3: 2 
 
[39] Population-based 399 Ab- ELISA 52.9  
[40] 
Patients with 
neurological 
symptoms 
1890 sera 
989 CSF 
52 sera + CSF
Ab-ELISA 
CTscan/MRI
14.9 82.2 
[41] Population-based 157 Ab-ELISA 28.7  
[42] Pig-breeders 46 EITB 8,7  
[43] Population-based 665 Ab-ELISA 28.4  
[44] PWE 111 Ab- ELISA 17,1  
[45] PWE 223 Ab-ELISA 35,9  
[46] Population-based 29360 Ab-ELISA 8.55  
Ecuador 
[47] Population-based 4306 Ag-ELISA 4.99  
[48] Population-based
2415 (24 
PWE) 
CT scan  33% PWE 
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Country Reference Type of study 
Subject 
included 
Diagnosis 
based on 
Seroprevalence 
Cysticercosis 
(%) 
Prevalence 
NCC 
[49] Population-based 800 
Ag-ELISA, 
EITB 
2.25  
[50] Hospital-based 
194 PWE 
(late-onset) 
CT scan/MRI  19.6* 
Haiti [51] Medical visits 216 EITB 2.8  
Honduras 
[52] Population-based
6473 (151 
PWE) 
EITB 
CT scan 
 37 (PWE) 
[53] Population-based
5609 (33 
PWE) 
EITB 
CT scan 
 13.9 (PWE) 
Mexico 
[54] Population-based 154 CT scan  9.1 
[55] Population-based 649 CT scan  9.1 
[56] 
Psychiatric  
patients 
105 
Ab-ELISA 
EITB 
7.6 (ELISA) 
0.9 (EITB) 
 
[57] PWE (late-onset) 455 CT scan  21.1 
[58] 
All NC patients 
diagnosed at 
INNN in 2004 
4706 
CT scan/ 
MRI 
 2.5 
Nicaragua [59] PWE 88 
Ab-ELISA 
EITB 
8.0 (ELISA) 
14.8 (EITB) 
 
Peru 
[60] Population-based 2583 EITB 13.9  
[61] Population-based 316 EITB 21  
[62] Population-based 903 
EITB (825)
CTscan (150)
24.2 27.3 
[63] Housemaids 1178 
EITB
CT-scan
14.6 
50 (of  
sero+) 
[64] Population-based 803 
EITB
CT-scan
24.4 3 
[65] Population-based 817 (8 PWE) 
EITB
CT-scan
 50 (PWE) 
[66] Population-based 368 
Ab-ELISA, 
EITB
3.3  
Venezuela 
[67] Population-based 68 
Ag/Ab 
ELISA
Ag: 64.7, Ab: 79  
[68] 
Population-based 
(3) 1254 
Ag/Ab  
ELISA 
Ag: 9.1; 6.1; 5.7 
Ab: 36.5;36.5; 4 
 
[69] Hospital-based 
158 
psychiatric 
patients 
127 controls
EITB 
Patients:18.3 
Controls:1.6 
 
EITB: Electro immune transfer blot; PWE: people with epilepsy. Ag: Circulating antigens of T. solium 
metacestodes, Ab: Antibodies anti-cysticercal.  * Only patients diagnosed between 2000 and 2009 were 
included. ** Cases of cysticercosis in general were reported
Table 2. Prevalence (sero prevalence) of human neurocysticercosis in Latin America.  
Only 2002-2012 articles were considered. 
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Country Reference Type of Study 
Subject 
included 
Diagnosis 
Based on 
seroprevalence 
Prevalence 
NCC 
China [70] Population-based 202 Ab-ELISA 2.97%. 
India 
[71] Population-based 72 CT-scan 26% 
[72] Hospital study 1026 PWE CT-scan 34.6% 
[73] Population-based 1063 EITB 15.9% 
[74] Population-based 450 Ab-ELISA 22.4% 
[75] Population-based 595 CT-scan 15.1% 
[76] Population-based 141 PWE CT-scan 24.8% 
[77] Population-based 1064 (sera) 
Ab / Ag-
ELISA 
CT-scan 
15.9% (Ac) / 
4.5% (Ag)  
[78] 
Neurological 
patients 
103 Ac-ELISA 33 (32%) 
 
[79] Population-based 
1442 controls 
91 suspected 
cases of NCC 
100 healthy 
students 
Indirect 
haemaggluti
nation (IHA)
6.1% controls 
21.97% 
suspected 
cases 0% 
healthy 
students 
 
[80] Blood donors 216 
Ab-ELISA / 
Ag-Co-
agglutination
14 (6.48 %) 
 
Indonésia 
[81] 
Population-based 
(1539 people) 
1120 cases of 
burns, 293 PWE 
(Papua)  / 
74 PWE, 746 
controls (Bali) 
Ab-ELISA 
67% PWE, 65% 
SCN (Papua)  
13.5% PWE 
12.5% controls 
(Bali) 
 
[82] Population-based 
17 PWE 
32 SCN 
47 control 
Ab-ELISA 
70.6% PWE 
62.5% SCN 
25.5% control 
 
[83] Population-based 96 Ab-ELISA 45.8% 
[84] Population-based 311 Ab-ELISA 0.3% 
Korea [85] Population-based 74,448 Ab-ELISA 
8.3% (1993)  
2.2% (2006)  
Malasya [86] Population-based 135 Ab-ELISA 2.2%. 
Nepal [87] Hospital study 300 PWE MRI 47% 
Philippines [88] Population-based 497 Ab-ELISA 24.6%  
Thailand [89] Population-based 159 Ab-ELISA 5.70% 
Viet Nam [90] Population-based 210 Ag-ELISA 5.7% 
 
[91] Population-based 
707 
(303 mountain, 
175 coast 
229 urban) 
Ag-ELISA, 
CT scan 
5.3% 
(mountain) 
0.6% (coast) 
0% (urban) 
 
PWE: people with epilepsy / SCN: subcutaneous nodules 
Table 3. Prevalence (seroprevalence) of human neurocysticercosis in Asia 
only 2002-2012 articles were considered. 
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Regarding porcine cysticercosis, diagnosis based on tongue inspection has been 
conventionally used, but does not detect all affected pigs. Serology permits, although not 
with ideal sensibility and specificity, identification of the areas where the life-cycle of the 
parasite persists. Echography (ultrasound) has recently been introduced as a sensitive (95%) 
and specific (97%) method of diagnosis (Kappa coefficient of 90%) [102]. Treatment of 
cysticercotic pigs with oxfendazole has shown a good efficiency [103].  
Diagnosis of the adult form of T. solium is perhaps the topic where more efforts must be 
made. Although a species-specific coproantigen ELISA was developed, reaching very good 
performance [104], further studies are required to evaluate it in field conditions. And this is 
not so easy, as prevalence of taeniosis seems to be much lower than that of cysticercosis, a 
fact understandable as one tapeworm carrier can infect hundreds of people and thousands 
of pigs. Treatment of taeniosis with niclosamide or praziquantel has shown to be very 
efficient [105].  
In conclusion, although efforts must continue  in some areas, today we have tools that allow 
the detection of endemic areas and the effective diagnosis and treatment of patients in most 
circumstances. This situation, adding to the existence of specific tools for prevention 
(vaccine), allows the design of extensive and effective preventive and control programs.  
3. Strategies to eradicate the disease 
Cysticercosis is considered a neglected “tools-ready disease” according to WHO [106] and as 
a potentially eradicable disease since 1993 [107].This is feasible because there are no animal 
reservoirs besides humans and pigs, the only source of T. solium infection for pigs being 
humans (the definitive host), interrupting the parasite´s life cycle seems an easy task by 
intervention strategies acting upon different stages of the parasite´s development. 
Different strategies have been proposed and tested, generally experimental and at small 
scale, to eradicate the (T/C) complex, the most notable being: 
1. Massive cestocidal treatment to humans in order to reduce the number of tapeworm 
carriers [108-110]. 
2. Health education programs aiming to promote the understanding of the mechanisms of 
transmission of the parasite and to improve hygienic behavior, pig-management and 
sanitary conditions which fosters transmission [111-113]. 
3. Treatment of infected pigs [103, 114-116].  
4. Vaccination of rural pigs: different vaccines have been tested in field conditions and 
have demonstrated their efficacy in preventing swine cysticercosis [117-120].  
5. Combinations of different strategies: pig vaccination and treatment [121], massive 
human cestocidal treatment associated with pig vaccination and treatment [122,123]. 
Almost all these strategies have shown some degree of efficacy, this fact contrasting with the 
persistence of the parasite in all the endemic countries in the 1950’s. It should be noted that, 
to our knowledge, programs promoting letrinization of rural communities and construction 
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of pig housing have not been tested (probably due to economic and logistic costs) although 
it seems to be a very efficient strategy for many parasitic and infectious disease transmitted 
by faeces. 
4. What must be done? 
This is a truly kafkian situation: we are in the presence of a parasite that causes a potentially 
severe human disease, as well as important economic losses; paradoxically, it is clear that 
the disease is potentially eradicable and, in fact, scientists and health authorities know how 
to eradicate it and have strategies to reach this goal. Despite all these resources, and their 
demonstrated effectiveness, the signs of a decrease of the transmission rate in the endemic 
countries are inconclusive or doubtful and, worse yet, in some non-endemic countries, an 
increase in the number of neurocysticercosis cases is occurring.  
Faced with this perspective, it becomes evident that we will not attain the eradication of T. 
solium without: 
4.1. The intervention of the national and international health authorities in 
control programs 
International initiatives have been concerned with the problem of cysticercosis for many 
years and several meetings were organised, the most important being: WHO Technical 
Consultation (Geneva, 1983), Pan American Health Organization (PAHO) Informal 
Consultation on Taeniasis/Cysticercosis (Porto Allegre, 1990), International Task Force for 
Disease Eradication (ITFDE, Atlanta, 1993), PAHO/WHO Informal Consultation on the 
Taeniasis/Cysticercosis Complex (Brasilia, 1995), North Atlantic Treaty Organization 
(NATO) Seminar on Emergent Helminth Zoonoses, (Pozna, 2000), Fifty-Fifth World Health 
Assembly, (Geneva, 2002), ITFDE II (Atlanta, 2003), WHO Expert Consultation on 
Foodborne Trematode Infections (Ventiane, 2009). In most of them, strategies for prevention 
and control of T/C were analyzed and recommendations were made. Since 2008, the WHO 
has included T/C in its Global Plan to combat Neglected Tropical diseases [124]. 
Regarding national health authorities, not much has been done. In very few countries, 
specific norms have been recommended. Such is the case of Latin America where only 
Mexico has an official norm for the vigilance, the prevention and the control of T/C in the 
first level of attention which was published in 1994 (modified in 2004) [125]. The Mexican 
norm includes the implementation of education and information programs, the 
identification and treatment of tapeworm carriers, the referral of subjects with suspected of 
NCC to a second level of attention, the confiscation of infected pigs, and the obligation to 
notify the diagnosed cases of NCC, taeniosis and swine cysticercosis to the corresponding 
authorities. The effort must be applauded, and has surely contributed to the awareness of 
the general population and of the medical personnel about the problem. Unfortunately, still, 
15 years after its promulgation, cases of swine and human cysticercosis are still being 
diagnosed and not notified in Mexico. Probably, this is due to the fact that this norm did not 
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reach the rural zones where the life-cycle of T. solium is still active and notification is not 
equally honored by all professionals (or because there are no health facilities in these areas).  
It is important to promote the confiscation of infected pigs, but who is going to pay the 
owners, and who will go to the endemic communities (for example >2500 municipalities in 
Mexico) and make the diagnosis in more than six million rural pigs that get renewed every 
year? Clearly, pig owners must be included in a control program, for the obvious reason 
that they are the most interested in not having infected pigs. 
It is highly relevant to promote the notification of infected individuals, but who will make 
this notification? Hospitals with an efficient epidemiologic department are scarce and 
medical doctors in public institutions are generally over loaded by the clinical workload. 
The comparison of the official statistics and the statistics published from only one hospital 
center can demonstrate the problem: in 2004, in the Instituto Nacional de Neurología y 
Neurocirugía, located in Mexico City, an institution that treats only patients lacking social 
security, 120 new cases of NCC were diagnosed [58], while in the official statistics, in this 
same year, approximately 400 new NCC cases were reported throughout Mexico [126]. It is 
very improbable that a sole institution accounts for a quarter of all the Mexican NCC cases, 
and probably this is due to a significant under-reporting of cases. Faced with this 
undesirable practice, what actions can the governments take? It is probably necessary: 1) to 
maintain a continuing health education program available to the population and the 
medical personnel, insisting on their obligation to notify the cases and promoting the 
establishment of epidemiological departments and surveillance system in all the hospitals, 
2) to actively lobby for the implementation of a National Control Program that could be 
started as a priority in the areas from where most cases are referred. In relation to this point, 
the critical question is, who can organize a preventive program? The scientists probably not, 
as the logistics of such programs require an established structure supported by a recognized 
local authority. Since 2009, in Mexico, an extensive pilot control program is under way, in 
certain areas of the poorest states, based on health and sanitary education and associated 
with vaccination of pigs. Local authorities are part of the efforts, helping with the 
identification of the endemic areas, by furnishing sera collected from the pigs, and by 
funding the program. The results so far are encouraging. People in the remote areas accept 
suggestions for improvement in their pig raising methods and for their personal hygiene, 
including the indispensable installation of latrines [127]. What has become clear is that 
programs must be of long duration, at least 5 years. It is of little use to visit communities, 
give talks, vaccinate pigs and leave. People in theses “forgotten” areas need long-lasting 
help, advice and supervision. Therefore, without the active participation of the 
governments, failure of any control program is predictable because scientists cannot apply it 
at large enough scales and sufficient time. Finally, the presence of cysticercosis is an 
objective indicator of unacceptable conditions in a rural community, and their improvement 
will not only contribute to the eradication of cysticercosis, but will also bring collateral 
benefits, such as the control of other soil transmitted diseases and increased public 
awareness of respect for adequate simple public health measures.  
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4.2. Implementation of regional networks 
As T. solium does not respect frontiers, it is necessary to organize multidisciplinary regional 
networks of specialists that must be the interlocutors of the local government and international 
organizations, and that must participate in the decision of where the preventive measures 
must be applied, and what type of measures are the most adequate regarding the individual 
characteristics of the country affected. Such efforts are currently established: 
- In Asia, the Regional Network for Asian Schistosomiasis and other important zoonoses 
(RNAS+) was created in 2006 (extension of the RNA created in 2000) and since this date 
has published several papers and has maintained discussions on preventive measures 
to be applied to effectively combat zoonoses.  
- In Africa: the Cysticercosis Working Group in Eastern and Southern Africa (CWGESA) 
was established in 2002 to promote communication, collaboration and coordination of 
integrated research and control activities to combat cysticercosis.  
- In Europe, The European Cysticercosis Working Group, inaugurated in 2008 and 
receiving organizational support from the World Health Organization (WHO)/Food 
and Agricultural Organization of the United Nations (FAO) Collaborating Centre for 
Parasitic Zoonoses in Denmark and the University of Edinburgh, Scotland, and aimed 
at finding ways to achieve a more effective, concerted approach to combat cysticercosis 
in Europe, as well as in the main cysticercosis-endemic areas of Africa, Asia, and Latin 
America [128].  
- In Latin America, since 1987, the Cysticercosis Working Group in Peru has made 
several epidemiological, diagnostic and control studies in this country [129] and 
recently a new Ibero-Latinamerican network was created to promote the investigation 
and the implementation of preventive measures in the entire continent.  
At the moment, although some objectives have been reached, their scope is still limited. To 
improve the situation, it is necessary: 1) to expand exchanges between the different 
networks; 2) to open ways of communication between these networks and the national and 
international authorities.  
In conclusion, to reach the control of T.solium infections it is very important to open new 
ways of communication between the scientists, grouped in networks, and with the 
international and the national health authorities. Agreements must be made in which the 
role and responsibilities of each of them are clearly defined. If one of these conditions fails, 
we are afraid that in 50 years, today’s T/C epidemiological situation will persist.  
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